Fasedienol Shows Efficacy Signal in Very Severe Social Anxiety Subgroup
VTGN sits 88% above its 52-week low of $0.198 on elevated volume (44× avg).
Summary
Vistagen presented new exploratory analyses at Psych Congress 2026 showing fasedienol nasal spray produced statistically significant improvements in anxiety symptoms among participants with very severe social anxiety disorder (LSAS ≥95). The post-hoc analysis from the failed PALISADE-4 Phase 3 trial found a significant benefit on SUDS scores during a public speaking challenge in this subgroup, despite the trial missing its primary endpoint in the overall population. A prespecified analysis from a Phase 2a repeat-dose study also showed significant improvement after a single dose and even greater numerical improvement after a second dose 10 minutes later. These findings follow the preliminary positive open-label extension data reported two days ago and provide a potential path forward for fasedienol in a more severely affected patient population. The company remains under going-concern doubt with cash runway uncertain beyond twelve months, so any positive efficacy signal is critical for its survival. Investors will watch whether these subgroup results support a new Phase 3 trial design or regulatory discussions.
At the time of this announcement, VTGN was trading at $0.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.3M. The 52-week trading range was $0.20 to $5.14. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.